



(43) International Publication Date 1 May 2003 (01.05.2003)

PCT

(10) International Publication Number WO 03/035926 A2

(51) International Patent Classification7: C23C 16/00

(21) International Application Number: PCT/GB02/04822

(22) International Filing Date: 25 October 2002 (25.10.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0125724.5

GB 26 October 2001 (26.10.2001)

0129080.8

4 December 2001 (04.12.2001)

(71) Applicant (for all designated States except US): EPICHEM LIMITED [GB/GB]; Power Road, Bromborough, Wirral CH62 3QF (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): JONES, Anthony, Copeland [GB/GB]; Rose Tree Cottage, Georgian Close, Eccleston Park, Prescot, Merseyside L35 7JW (GB).

(74) Agent: ROYSTONS; Liverpool Office, Tower House, Water Street, Liverpool L3 1BA (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMPROVED PRECURSORS FOR CHEMICAL VAPOUR DEPOSITION

(57) Abstract: Ti, Zr Hf and La precursors for use in MOCVD techniques have a ligand of the general formula OCR1(R2)CH2X, wherein R1 is H or an alkyl group, R2 is an optionally substituted alkyl group and X is selected from OR and NR2, wherein R is an alkyl group or a substituted alkyl group.

Improved precursors for chemical vapour deposition

Description

This invention concerns precursors for chemical vapour deposition.

This invention is particularly, but not exclusively concerned with precursors for the growth of zirconium oxide (ZrO₂), hafnium oxide (HfO₂), zirconium oxide/silicon oxide (ZSO) and hafnium oxide/silicon oxide (HSO) by chemical vapour deposition.

Thin films of ZrO₂ and HfO₂ and the related silicates ZSO and HSO have important technological applications. In particular, they have high permittivities and are relatively stable in contact with silicon, making them the prime candidates to replace SiO₂ as gate dielectric layers in next-generation MOSFET devices in integrated SI circuits. Metalorganic chemical vapour deposition (MOCVD) is an attractive technique for the deposition of these materials, offering the potential for large area growth, good composition control and film uniformity, and excellent conformal step coverage at device dimensions less than 2μm, which is particularly important in microelectronics applications.

An essential requirement for a successful MOCVD process is the availability of precursors with the appropriate physical properties for vapour phase transport and a suitable reactivity for deposition. There must be an adequate temperature window between evaporation and decomposition, and for most electronics applications oxide deposition is restricted to temperatures

in the region of 500°C, to prevent degradation of the underlying silicon circuitry and metal interconnects.

There are a number of problems associated with existing Zr and Hf CVD precursors. For instance, the halides ZrCl₄ and HfCl₄ are low volatility solids which need substrate temperatures of 800°C and above for oxide deposition. Metal β -diketonates, such as [Zr(thd)₄] (thd = 2,2,6,6tetramethylheptane-3,5-dionate) also require high substrate temperatures (> 600°C) for oxide growth. These are incompatible with the requirements of the electronics industry. Metal alkoxides are more attractive CVD precursors as they allow lower deposition temperatures. However, the majority of [Zr(OR)4] and [Hf(OR)4] complexes are dimeric or polymeric with limited volatility, due to the pronounced tendency of the Zr(IV) and Hf(IV) to expand their coordination sphere to six, seven or eight. In order to inhibit oligomerisation, sterically demanding ligands such as tert-butoxide have been employed, and [Zr(OBu^t)₄] (D.C. Bradley, Chem. Rev. 1989, 89, 1317) and [Hf(OBu^t)₄] (S. Pakswer & P Skoug, in "Thin dielectric oxide films made by oxygen assisted pyrolysis of alkoxides", The Electrochem. Soc., Los Angeles, CA, USA, 1970, 619 - 636) have been successfully used for the CVD of ZrO2 and HfO2. However, these mononuclear precursors contain unsaturated four-coordinate metal centres and the tert-butoxide ligand undergoes a catalytic decomposition reaction in the presence of trace water. This makes them highly air and moisture sensitive and susceptible to pre-reaction in the CVD reactor. Their reactivity also leads to a greatly reduced shelf life, especially in solution-based liquid injection CVD applications.

An object of this invention is to provide stable and volatile Ti, Zr and Hf precursors suitable for use in chemical vapour deposition techniques.

It has been surprisingly found that the donor functionalised alkoxy ligand 1-methoxy-2-methyl-2-propanolate [OCMe₂CH₂OMe, mmp] is effective in inhibiting oligomerisation in Zr and Hf alkoxide complexes, as well as increasing the ambient stability of the complexes.

Accordingly the present invention provides Ti, Zr, Hf and La precursors for use in MOCVD techniques having a ligand of the general formula OCR¹(R²)CH₂X, wherein R¹ is H or an alkyl group, R² is an optionally substituted alkyl group and X is selected from OR and NR₂, wherein R is an alkyl group or a substituted alkyl group.

Precursors according to a first preferred embodiment of the invention have the following general formula:

M(L)_x[OCR¹(R²)CH₂X]_{4-x}

wherein M is a metal selected from Ti, Zr and Hf, L is a ligand, x is a number from 0 to 3 and R^1 , R^2 and X are as defined above.

The preferred ligand L is an alkoxy group having from 1 to 4 carbon atoms, of which tertiary-butoxide (OBu^t) group is most preferred, although other groups such as iso-propoxide (OPr^I) can be employed.

The preferred ligand of the formula $OCR^1(R^2)CH_2X$ is 1-methoxy-2-methyl-2-propanolate (mmp) but other donor functionalised alkoxide ligands may also carry out the desirable function of inhibiting oligomerisation in Zr, Hf and Ti alkoxides for use in the invention. These include but are not limited to

 $\label{eq:ch2OMe} OCH(Me)CH_2OMe,\ OCEt_2CH_2OMe,\ OCH(Bu^t)CH_2OEt,\ OC(Bu^t)_2CH_2OEt, \\ OC(Pr^l)_2CH_2OEt,\ OCH(Bu^t)CH_2NEt_2,\ OC(Pr^l)_2CH_2OC_2H_4OMe\ and \\ OC(Bu^t)(CH_2OPr^l)_2\ .$

The invention further provides a method of making Ti, Zr and Hf precursors for use in MOCVD techniques comprising reacting mmpH with the corresponding metal alkoxide or metal alkylamide in appropriate molar proportions.

The new alkoxide complexes Zr(OBu¹)_Z(mmp)₂, Zr(mmp)₄, Hf(OBu¹)_Z(mmp)₂, and Hf(mmp)₄ have been synthesised by the addition of mmpH to Zr(OBu¹)₄ and Hf(OBu¹)₄ in appropriate molar proportions. The complexes have high vapour pressures suitable for MOCVD, and are also much less reactive to air and moisture than Zr(OR)₄ compounds, wherein R is an alkyl group, making them easier to handle and use in MOCVD. The reduced air-sensitivity of these new Zr and Hf complexes arises from the replacement of the highly moisture sensitive *tert*-butoxide groups in [Zr(OBu¹)₄] and [Hf(OBu¹)₄] with the mmp ligand, which is much less susceptible to hydrolysis. The complexes are further stabilised to hydrolysis by an increase in the coordination number of the central Zr or Hf atom.

According to a second preferred embodiment the invention can be extended to other metals, which have large atomic radii and are highly positively charged, such as lanthanum, in which case preferred precursors have the following general formula

La[OCR1(R2)CH2X]3

wherein R^1 is H or an alkyl group, R^2 is an optionally substituted alkyl group and X is selected from OR and NR₂,wherein R is an alkyl group or a substituted alkyl group.

The preferred ligand for this preferred embodiment of the invention is 1-methoxy-2-methyl-2-propanolate [OCMe₂CH₂OMe], although other donor functionalised alkoxide ligands may be used. These may include but are not limited to OCH(Me)CH₂OMe, OCEt₂CH₂OMe, OCH(Bu^t)CH₂OEt, OC(Bu^t)₂CH₂OEt, OC(Pr^l)₂CH₂OEt, OCH(Bu^t)CH₂NEt₂, OC(Pr^l)₂CH₂OC₂H₄OMe and OC(Bu^t)(CH₂OPr^l)₂.

The invention also provides a preferred method of making precursors according to the second preferred embodiment comprising reacting mmpH with La{N(SiMe₃)₂}₃ in appropriate molar proportions.

Precursors according to the invention may be used in depositing single or mixed oxide layers or films by conventional MOCVD, in which the precursor is contained in a metalorganic bubbler, or by liquid injection MOCVD, in which the precursor is dissolved in an appropriate inert organic solvent and then evaporated into the vapour phase using a heated evaporator. The precursors may also be suitable for use in the deposition of zirconium oxide, hafnium oxide and titanium oxide films by other chemical vapour deposition techniques, such as atomic layer deposition (ALD).

The precursors can be used for the MOCVD of ZrO₂, HfO₂, and TiO₂, La₂O₃, and in combination with other precursors for the MOCVD of complex

oxides containing zirconium oxide, hafnium oxide, and lanthanum oxide such as ZSO and HSO and La-silicate.

The precursors can also be used in combination for the MOCVD of complex oxides. Examples include the MOCVD of bismuth-titanate from the combinations Bi(mmp)₃ / Ti(OPr¹)₂(mmp)₂ or Bi(mmp)₃ / Ti(mmp)₄.

The invention will now be further described with reference to the accompanying drawings, in which:

Figure 1 shows an envisaged structure for $M(OBu^t)_2(mmp)_2$ (M = Zr or Hf);

Figure 2 shows the molecular structure of Hf(mmp)₄. Zr(mmp)₄ has a similar structure; and

Figure 3 shows laser Raman spectra ZrO₂ and HfO₂ films grown by liquid injection MOCVD using Zr(OBu^t)₂(mmp)₂ or Hf(OBu^t)₂(mmp)₂.

The invention will now be further described by means of the following Examples.

Example 1

Preparation of Zr(OBut)2(mmp)2

2.8 ml (2.69 g, 7.0 mmol) Zr(OBu^t)₄ was dissolved in hexane (*ca.* 40 ml). mmpH (1.6 ml, 1.44 g, 13.9 mmol) was added dropwise, the mixture was heated to reflux and stirring continued for a further 2 hours. The solution was cooled to room temperature and the volatiles removed by evaporation under reduced pressure. The product was recrystallised from hexane to give a white crystalline solid.

M.pt.: 96 - 101 °C (uncorrected)

Microanalysis: Calc. C: 48.71, H: 9.10. Found: C: 46.32, H: 8.77%

¹H NMR: (400MHz, d₈-tol) 1.19 (s, 12H, OC(*CH*₃)₂CH₂OCH₃), 1.37 (s, 18H,

 $OC(CH_3)_3$), 3.23 (s, 4H, $OC(CH_3)_2CH_2OCH_3$), 3.40 (s, 6H,

 $OC(CH_3)_2CH_2OC\underline{H}_3$).

¹³C NMR: 34.1 (OC(<u>CH₃</u>)₂CH₂OCH₃), 38.5 (OC(<u>CH₃</u>)₃), 65.4 (OC(CH₃)₂CH₂O<u>C</u>H₃), 78.6 (O<u>C</u>(CH₃)₂CH₂OCH₃ and O<u>C</u>(CH₃)₃), 90.5 (OC(CH₃)₂CH₂OCH₃).

IR: (v cm⁻¹, Nujol, NaCl) 3588(w), 3442(w), 2725(m), 2360(w), 1356(s), 1277(m), 1227(m), 1206(s), 1177(s), 1115(s), 1080(s), 1012(s), 974(s), 936(s), 801(s), 782(s), 595(s).

An envisaged structure for $Zr(OBu^t)_2(mmp)_2$ is shown in Figure 1 of the drawings.

Example 2

Preparation of Zr(mmp)₄

2.0 g (5.2 mmol) Zr(OPr¹)₄•Pr¹OH was dissolved in hexane (*ca.* 40 ml). mmpH (2.6 ml, 2.35 g, 22.5 mmol) was added dropwise, the mixture heated to reflux and stirring was continued for 2 hours. The mixture cooled to room temperature and the volatiles was removed by evaporation under reduced pressure to give the product as a white viscous oil. (Yield: 2.4 g, 94%).

Zr(mmp)₄ can also be synthesised from the corresponding zirconium alkylamide complexes, Zr(NR₂)₄. For instance, by the dropwise addition of mmpH (6.9g, 65.8 mmol) to a stirred solution of [Zr(NEt₂)₄] (5.0g, 13.2 mmol) in hexane (50 cm³). The mixture was boiled under reflux for 2 hr. and then

allowed to cool to room temperature. Volatiles were removed in vacuo to give the product (yield 6.25 g, 94%).

Microanalysis: Calc. C: 47.67, H: 8.82 Found: C:47.80, H: 8.79%.

¹H NMR: (400 MHz, d₈-tol): 1.21 (s, OC(C<u>H₃)</u>₂CH₂OCH₃), 3.16 (s,

 $OC(CH_3)_2CH_2OCH_3$), 3.27 (s, $OC(CH_3)_2CH_2OCH_3$)

¹³C NMR: (100 MHz, d₈-tol): 32.1 (OC(<u>C</u>H₃)₂CH₂OCH₃), 64.8

 $(OC(CH_3)_2CH_2O\underline{C}H_3)$, 76.0 $(O\underline{C}(CH_3)_2CH_2OCH_3)$, 88.5 $(OC(CH_3)_2\underline{C}H_2OCH_3)$.

IR: (v cm⁻¹, Nujol, NaCl) 3589(w), 3448(w,br), 2724(m), 2346(w), 1377(s),

1322(m), 1279(m), 1239(m), 1176(s), 1134(m), 1114(s), 1081(m), 1018(s),

996(m), 982(s), 958(m), 937(m), 917(m), 845(m), 804(m), 784(m), 594(s).

Example 3

Preparation of Hf(OBut)2(mmp)2

3.5 ml (4.0 g, 8.5 mmol) Hf(OBu^t)₄ was dissolved in hexane (*ca.* 40 ml) to give a yellow solution. MmpH (2.0 ml, 1.79 g, 19.0 mmol) was added dropwise, the mixture heated to reflux and stirring continued for 2 hours. The solution was allowed to cool and the volatiles removed by boiling under reduced pressure. The crude product was recrystallised from hexane to give a white crystalline solid.

(Yield: 4.4 g, 97%).

M. Pt: 100 - 104 ° C (uncorrected)

Microanalysis: Calc. C: 40.71, H: 7.61. Found. C: 38.93, H: 7.30%

¹H NMR: (400 MHz, d_8 -tol): δ = 1.18 (s, 12H, OC(CH_3)₂CH₂OCH₃), 1.38 (s,

18H, OC(CH₃)₃), 3.21 (s, 12H, OC(CH₃)₂CH₂OCH₃), 3.42 (s, 12H,

 $OC(CH_3)_2CH_2OCH_3$

¹³C NMR: (100 MHz d₈-tol): δ = 34.4 (OC($\underline{C}H_3$)₂CH₂OCH₃), 38.6 (OC($\underline{C}H_3$)₃), 65.7, (OC(CH₃)₂CH₂O $\underline{C}H_3$), 78.0, 79.1 (O \underline{C} (CH₃)₂CH₂OCH₃ and O \underline{C} (CH₃)₃), 90.9 (OC(CH₃)₂ $\underline{C}H_2$ OCH₃),

IR: (υ cm⁻¹, Nujol, NaCl): 3441(w), 2726(m), 2256(w), 1272(s), 1177(s), 1074(s), 1016(s), 976(s), 802(s), 782(s), 593(s).

An envisaged structure for Hf(OBu^t)₂(mmp)₂ is shown in Figure 1 of the drawings.

Example 4

Preparation of Hf(mmp)4

4.0 ml (5.56 g, 11.9 mmol) [Hf(NEt₂)₄] was dissolved in hexane (60 ml). Hmmp (7.0 ml, 6.3 g, 60 mmol) was added dropwise and the mixture refluxed for 90 mins. Volatiles were removed in vacuo to give the product as a yellow viscous oil.

(Yield: 6.88 g, 97.5 %).

Microanalysis: Calc. C: 40.63, H: 7.52. Found. C39.85, H 7.32%

¹H NMR: 1.30 (s, 24H, OC(CH₃)₂CH₂OCH₃), 3.28 (s, 8H, OC(CH₃)₂CH₂OCH₃), 3.36 (s, 12H, OC(CH₃)₂CH₂OCH₃)

¹³C NMR: 34.74 (OC(<u>C</u>H₃)₂CH₂OCH₃), 65.16 (OC(CH₃)₂CH₂O<u>C</u>H₃), 79.83 (O<u>C</u>(CH₃)₂CH₂OCH₃), 90.25 (OC(CH₃)₂<u>C</u>H₂OCH₃)

IR: (Nujol/NaCl): 3585(w), 3450(w,br), 2722(m), 1366(s), 1356(vs), 1268(s), 1242(s), 1214(vs), 1177(vs), 1115(vs), 1079(vs), 1045(vs), 1026(vs), 996(vs), 975(vs), 936(vs), 912(m), 802(s), 779(s), 594(vs).

An envisaged structure for Hf(mmp)₄ is shown in Figure 2 of the accompanying drawings.

Example 5

Preparation of Zr(OPr¹)₂(mmp)₂

1.06 g (2.75 mmol) Zr(OPr¹)₄•Pr¹OH was dissolved in hexane (*ca* 40 ml). 1-methoxy-2-methyl-2-propanol [mmpH] (0.65 ml, 0.57 g, 5.5 mmol) was added dropwise, the mixture was heated to reflux and stirring continued for a further 2 hours. The solution was cooled to room temperature and the volatiles removed by evaporation under reduced pressure. The product was isolated as a white viscous oil.

Microanalysis: Calc. C: 46.23, H: 8.73. Found: C: 44.17, H: 8.47

¹H NMR (400MHz, d₈-tol): 1.26 (s, OC(*CH*₃)₂CH₂OCH₃), 1.32 (d, OCH(*CH*₃)₂), 3.26 (2, OC(CH₃)₂CH₂OCH₃), 3.36 (s, OC(CH₃)₂CH₂OCH₃), 4.46 (m, OCH(CH₃)₂).

¹³C NMR (100MHz, d₈-tol): 32.1 (OC($\underline{C}H_3$)₂CH₂OCH₃), 34.2 (OCH($\underline{C}H_3$)₂), 64.9 (OC(CH₃)₂CH₂O $\underline{C}H_3$), 76.1, 76.4 (O $\underline{C}H$ (CH₃)₂ and O \underline{C} (CH₃)₂CH₂OCH₃), 88.6 (OC(CH₃)₂ $\underline{C}H_2$ OCH₃).

IR: (υ cm⁻¹, Nujol, NaCl) 3589(w), 3423(w), 2724(w), 2282(w), 1239(w), 1175(m), 1115(m), 1019(m), 959(m).

Example 6

Preparation of Ti(OPrⁱ)₂(mmp)₂

MmpH (2.81g, 27mmol) was added dropwise to 0.0135moles) to a stirred solution of $Ti(OPr^{i})_{4}$ (3.84g, 13.5mmol) in hexane (20 ml). The mixture was boiled under reflux for $1^{1}/_{2}$ hours and was then allowed to cool. The solvent was then removed *in vacuo* to give $Ti(OPr^{i})_{2}$ (mmp)₂ as a colourless oil.

Microanalysis for $TiC_{16}H_{36}O_4$: (calculated) C% 51.61, H% 9.75; (experimental) C% 51.20, H% 9.92.

¹H NMR (C₆D₅CD₃ at 30°C) δ 1.1 (26H, d, (CH₃)₂CH; CH₃OCH₂(CH₃)₂C); δ 3.2 (10H, two singlets, CH₃OCH₂(CH₃)₂C); δ 4.5 (2H, m, (CH₃)₂CH).

13C{¹H} NMR (C₆D₅CD₃, 30°C): 32 (OC(CH₃)₂CH₂OCH₃), 33.4 (OCH(CH₃)₂), 64.4 (OC(CH₃)₂CH₂OCH₃), 81.7 (OC(CH₃)₂CH₂OCH₃ 86.5 (OCH(CH₃)₂), 88

IR (Nujol, cm⁻¹) 2972s, 2928s, 2869s, 2625w, 1463m, 1376m, 1360s, 1331m, 1277m, 1126s, 1001s, 850s, 778m., 629s.

Example 7

 $(OC(CH_3)_2CH_2OCH_3).$

Preparation of Ti(mmp)₄

MmpH (4.41g, 42 mmol) was added dropwise to a stirred solution of $Ti(NEt_2)_4$ (2.85g; 3ml; 8.47mmole) in hexane (20 ml) resulting in pale brown solution. The mixture was boiled under reflux for $1^1/_2$ hours, allowed to cool, and then volatiles were removed *in vacuo* to give $Ti(mmp)_4$ as a pale brown oil.

Microanalysis for $TiC_{20}H_{44}O_8$: (calculated) C% 52.17, H% 9.63; (experimental) C% 51.95, H% 9.97.

 1 H NMR (C₆D₅CD₃ at 30°C) δ 1.3 (24H, s, CH₃OCH₂(CH₃)₂C); δ 3.2 (20H, two singlets, CH₃OCH₂(CH₃)₂C). VT 1 H NMR showed sharp distinct peaks from -50 to +50 °C - no broadening was apparent.

¹³C{¹H} NMR (C₆D₅CD₃, 30°C): 31.9 (OC(<u>C</u>H₃)₂CH₂OCH₃), 64.5 (OC(CH₃)₂CH₂O<u>C</u>H₃), 81.7 (O<u>C</u>(CH₃)₂CH₂OCH₃), 87 (OC(CH₃)₂<u>C</u>H₂OCH₃). IR (Nujol, cm⁻¹) 2975s, 2931s, 2876s, 2829m, 2625w, 1461m, 1360s, 1331m, 1277m, 12406m, 1116s, 1004s, 850m., 796s, 775s, 625s.

Example 8

Preparation of La(mmp)₃

[La{N(SiMe₃)₂}₃] (2.89 g, 4.6 mmol) was dissolved in toluene (50 ml) and mmpH (2.2 ml, 1.96 g, 18.7 mmol) added dropwise under stirring. Stirring was continued at room temperature for a further 21 hours and the volatiles removed *in vacuo* to give the product as a brown viscous oil (Yield = 1.8 g, 87% with respect to La)

Microanalysis for LaC₁₅H₃₃O₆(calculated) C % 40.18, H % 7.43; (experimental) C % 40.01, H % 7.38

Example 9

Zirconium oxide and hafnium oxide deposition from Zr(OBu^t)₂(mmp)₂, Zr(mmp)₄, Hf(OBu^t)₂(mmp)₂ and Hf(mmp)₄
All four complexes were found to be excellent precursors for the deposition of ZrO₂ and HfO₂ thin films by MOCVD. The ZrO₂ and HfO₂ films were deposited by liquid injection MOCVD using the same general conditions shown in Table 1 below.

Table 1

Growth conditions used for the growth of ZrO_2 or HfO_2 thin films by liquid injection MOCVD using $Zr(OBu^t)_2(mmp)_2$, $Zr(mmp)_4$, $Hf(OBu^t)_2(mmp)_4$ or $Hf(mmp)_4$

Substrate temperature	350-650 °C
Reactor pressure	20-30 mbar
Precursor solution concentration	0.1M in toluene
Precursor solution injection rate	4 – 8 cm ³ hr ⁻¹
Evaporator temperature	130 – 150°C
Argon carrier gas flow rate	400 – 600 cm ³ min ⁻¹
Oxygen flow rate	100 – 150 cm ³ min ⁻¹
Substrates	Si(100)
Oxide growth rate	0.35 – 0.50 μm hr ⁻¹

The identity of the films was confirmed as ZrO_2 or HfO_2 by laser Raman spectroscopy (see Figure 3). Raman spectra of ZrO_2 and HfO_2 films grown from $Zr(OBu^t)_2(mmp)_2$ or $Hf(OBu^t)_2(mmp)_2$ are shown in Fig. 3. Comparison with bulk crystalline data showed that these films were predominantly in the α -or monoclinic phase.

CLAIMS

- 1. Ti, Zr, Hf and La precursors for use in MOCVD techniques having a ligand of the general formula OCR¹(R²)CH₂X, wherein R¹ is H or an alkyl group, R² is an optionally substituted alkyl group and X is selected from OR and NR₂, wherein R is an alkyl group or a substituted alkyl group.
- 2. A precursor for use in MOCVD techniques having the following general formula:

M(L)_x[OCR¹(R²)CH₂X]_{4-x}

wherein M is a metal selected from Ti, Zr and Hf, L is a ligand, x is a number from 0 to 3 and R^1 , R^2 and X are as defined above.

- 3. A precursor as claimed in claim 2, wherein the ligand L is an alkoxy group having from 1 to 4 carbon atoms.
- 4. A precursor as claimed in claim 3, wherein the ligand L is selected from tertiary-butoxide (OBu^t) and iso-propoxide (OPrⁱ).
- 5. A precursor as claimed in any one of claims 1 to 4, wherein the ligand of the formula $OCR^1(R^2)CH_2X$ is 1-methoxy-2-methyl-2-propanolate (mmp).
- 6. A precursor as claimed in any one of claims 1 to 4, wherein the ligand of the formula $OCR^1(R^2)CH_2X$ is selected from $OCH(Me)CH_2OMe$, $OCEt_2CH_2OMe$, $OCH(Bu^t)CH_2OEt$, $OC(Bu^t)_2CH_2OEt$, $OC(Pr^l)_2CH_2OEt$, $OC(Pr^l)_2CH_2OEt$, $OCH(Bu^t)CH_2NEt_2$, $OC(Pr^l)_2CH_2OC_2H_4OMe$ and $OC(Bu^t)(CH_2OPr^l)_2$.
- 7. $Zr(OBu^t)_2(mmp)_2$.
- 8. Zr(mmp)_{4.}

- 9. Hf(OBu^t)₂(mmp)₂.
- 10. Hf(mmp)₄
- 11. A method of making Ti, Zr and Hf precursors for use in MOCVD techniques comprising reacting HOCR¹(R²)CH₂X with the corresponding metal alkoxide or metal alkylamide in appropriate molar proportions.
- 12. A precursor for use in MOCVD techniques having the following general formula

La[OCR1(R2)CH2X]3

wherein R^1 is H or an alkyl group, R^2 is an optionally substituted alkyl group and X is selected from OR and NR_2 , wherein R is an alkyl group or a substituted alkyl group.

- 13. A precursor as claimed in claim 12, wherein the ligand is 1-methoxy-2-methyl-2-propanolate [OCMe₂CH₂OMe].
- 14. A precursor as claimed in claim13, wherein the ligand is selected from OCH(Me)CH₂OMe, OCEt₂CH₂OMe, OCH(Bu^t)CH₂OEt, OC(Bu^t)₂CH₂OEt, OC(Pr^J)₂CH₂OEt, OCH(Bu^t)CH₂NEt₂, OC(Pr^J)₂CH₂OC₂H₄OMe and OC(Bu^t)(CH₂OPr^J)₂.
- 15. La[mmp]_{3.}
- 16. A method of making precursors as claimed in claim 12 comprising reacting $HOCR^1(R^2)CH_2X$ with $La\{N(SiMe_3)_2\}_3$ in appropriate molar proportions.
- 17. A method of depositing single or mixed oxide layers or films by conventional MOCVD, in which the precursor is contained in a metalorganic bubbler, or by liquid injection MOCVD, in which the precursor is dissolved in

an appropriate inert organic solvent and then evaporated into the vapour phase using a heated evaporator, wherein at least one of the precursors is as defined in any one of claims 1 to 10 and 12 to 15.





FIG.1



SUBSTITUTE SHEET (RULE 26)

1 24 Car 20




FIG.3